Dr. Rajiv Agarwal is a tenured Professor of Medicine at Indiana University School of Medicine at Indianapolis, IN. Dr. Agarwal earned his medical degree from the All India Institute of Medical Sciences in New Delhi. After completing residency in Internal Medicine at the same institution he completed a Nephrology fellowship at University of Texas, Southwestern Dallas. In July 1997, he joined Indiana University as Clinical Assistant Professor and within 10 years was promoted to the rank of full Professor. Dr. Agarwal has published over 200 original papers and reviews in Nephrology. He has had numerous invited lectures including those from national societies such as National Kidney Foundation, American Society Nephrology, International Society of Nephrology and the American Heart Association. Dr. Agarwal has received the Indiana University Trustee’s teaching award and the young scholar award of the American Society of Hypertension. He serves on the Editorial Board of Kidney International, CJASN, Hypertension and Seminars in Dialysis and as an Editor for several journals such as NDT, American Journal of Nephrology, Journal of the American Society of Hypertension and NephSAP.
Dr. Agarwal is an internationally recognized leader in the area of clinical and translational research in nephrology. He was amongst the first to demonstrate the effect of add-on angiotensin receptor blockade on cytokine production, oxidative stress, and proteinuria in patients with chronic kidney disease. He has developed a technique for measurement of oxidative stress biomarkers using HPLC and applied this method to demonstrate generation of oxidative stress with intravenous iron in patients with chronic kidney disease. These observations are amongst the first to demonstrate the presence, extent, and importance of oxidative stress in the progression of renal disease in humans. His foremost contribution has been in the area of hypertension in hemodialysis patients for which he is funded by the National Institutes of Health. He has refined the techniques to diagnose and treat hypertension in this complex group of patients. He was among the first to describe the antiproteinuric effects of vitamin D receptor activators. His research on anemia and iron management among patients with CKD is internationally recognized. He serves on the Board of Directors of KDIGO and has served as a panelist for Medical Evidence Development Coverage Advisory Committee (MEDCAC) for United States Medicare.